• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Chain Bridge I Will Redeem Public Shares

    10/31/23 4:00:00 PM ET
    $CBRG
    Blank Checks
    Finance
    Get the next $CBRG alert in real time by email

    Chain Bridge I (the "Company") (NASDAQ:CBRGU, CBRG, CBRGW))), a special purpose acquisition company, today announced that it will redeem all of its outstanding Class A ordinary shares, par value $0.0001 (the "Public Shares"), effective as of the close of business on November 15, 2023, as the Company will not consummate an initial business combination within the time period required by its Amended and Restated Memorandum and Articles of Association (the "Articles").

    The Company concluded it would be unable to meet its expectations for quality and long-term return potential by completing an initial business combination by November 15, 2023 (twenty-four months from the closing of the Company's initial public offering).

    The Company has shared a Letter to Investors with details on this decision that can be found as Exhibit 99.2 to the Form 8-K filed by the Company on October 31, 2023.

    As such, in accordance with the Company's Articles, the Company will:

    • cease all operations as of November 15, 2023, except those required to wind up the Company's business ;
    • as promptly as reasonably possible, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Company's trust account (the "Trust Account"), including interest earned on the funds held in the Trust Account and not previously released to the Company to pay the Company's income taxes, if any (less $100,000 of interest to pay dissolution expenses), divided by the number of the then-outstanding Public Shares, which redemption will completely extinguish public shareholders' rights as shareholders of the Company (including the right to receive further liquidation distributions, if any); and
    • as promptly as reasonably possible following such redemption, subject to the approval of the Company's remaining shareholders and the Company's board of directors, liquidate and dissolve, subject to the Company's obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law.

    The per-share redemption price for the public shares will be approximately $10.80 (the "Redemption Amount"). The balance of the Trust Account as of October 30, 2023 was approximately $44,947,177.68, which includes approximately $2,605,610.88 in interest and dividend income (excess of cash over $42,341,566.80, the funds deposited into the Trust Account). In accordance with the terms of the related trust agreement, the Company expects to retain $100,000 of the interest and dividend income from the Trust Account to pay dissolution expenses.

    As of the close of business on November 15, 2023, the Public Shares will be deemed cancelled and will represent only the right to receive the Redemption Amount.

    The Redemption Amount will be payable to the holders of the Public Shares upon presentation of their respective stock or unit certificates or other delivery of their shares or units to the Company's transfer agent, Continental Stock Transfer & Trust Company. Beneficial owners of Public Shares held in "street name," however, will not need to take any action in order to receive the Redemption Amount.

    There will be no redemption rights or liquidating distributions with respect to the Company's warrants, which will expire worthless.

    Our initial shareholders, including the Company's Sponsor and CB Co-Investment LLC, have agreed to waive their redemption rights with respect to the outstanding Class A ordinary shares, held by the them, and the Class B ordinary shares. After November 15, 2023, the Company shall cease all operations except for those required to wind up the Company's business.

    The Company expects that the Nasdaq Stock Market will file a Form 25 with the U.S. Securities and Exchange Commission (the "Commission") to delist its securities. The Company thereafter expects to file a Form 15 with the Commission to terminate the registration of its securities under the Securities Exchange Act of 1934, as amended.

    Forward-Looking Statements

    This press release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this press release, the words "could," "should," "will," "may," "believe," "anticipate," "intend," "estimate," "expect," "project," the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. Such forward-looking statements are based on current information and expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing the Company's views as of any subsequent date, and the Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. You should not place undue reliance on these forward-looking statements. As a result of a number of known and unknown risks and uncertainties, actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the "Risk Factors" in the Company's registration statement on Form S-1 (Registration No. 333-254502), as amended, initially filed with the Commission on March 19, 2021, relating to its initial public offering, annual, quarterly reports and subsequent reports filed with the Commission, as amended from time to time. Copies of such filings are available on the Commission's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20231031855541/en/

    Get the next $CBRG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CBRG

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CBRG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Phytanix Bio Publishes New Investor Deck Highlighting Strategic Vision and Growth Potential

      NEW YORK and SANTA BARBARA, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Phytanix Bio, a pioneering preclinical stage pharmaceutical company dedicated to the development of therapeutics based on cannabinoid and cannabinoid-like molecules, today announced the release of its new investor deck. The updated presentation provides an in-depth look at the company's strategic vision, scientific advancements, and growth potential as it progresses towards the development of next-generation cannabinoid medicines. The global cannabis pharmaceuticals market size was estimated at USD 3.4 billion in 2023 and is anticipated to grow at a CAGR of 53.3% from 2024 to 2030. The investor deck is now available on

      7/30/24 9:00:00 AM ET
      $CBRG
      Blank Checks
      Finance
    • Chain Bridge I to Acquire Phytanix Bio, Creating a New Public Company Focused on Developing Next Generation Cannabinoid and Cannabinoid-like Medicines

      Phytanix Bio is a preclinical stage pharmaceutical company founded by former members and associates of GW Pharmaceuticals, holding exclusive cannabinoid and cannabinoid-like medicine intellectual property (IP)The transaction reflects a pre-deal valuation of $58 million for Phytanix Bio plus the assumption of $17 million of preferred stock and $4.4 million of short-term debt that will be exchanged for convertible preferred stock at deal closeThe business combination is expected to be completed in the fourth quarter of 2024, with the combined company to be listed on Nasdaq Capital Markets under the ticker "PHYX" NEW YORK and SANTA BARBARA, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Phytani

      7/22/24 5:45:34 PM ET
      $CBRG
      Blank Checks
      Finance
    • Chain Bridge I Will Redeem Public Shares

      Chain Bridge I (the "Company") (NASDAQ:CBRGU, CBRG, CBRGW))), a special purpose acquisition company, today announced that it will redeem all of its outstanding Class A ordinary shares, par value $0.0001 (the "Public Shares"), effective as of the close of business on November 15, 2023, as the Company will not consummate an initial business combination within the time period required by its Amended and Restated Memorandum and Articles of Association (the "Articles"). The Company concluded it would be unable to meet its expectations for quality and long-term return potential by completing an initial business combination by November 15, 2023 (twenty-four months from the closing of the Company

      10/31/23 4:00:00 PM ET
      $CBRG
      Blank Checks
      Finance

    $CBRG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Chain Bridge I

      SC 13G/A - Chain Bridge I (0001845149) (Subject)

      11/14/24 1:46:48 PM ET
      $CBRG
      Blank Checks
      Finance
    • Amendment: SEC Form SC 13G/A filed by Chain Bridge I

      SC 13G/A - Chain Bridge I (0001845149) (Subject)

      11/14/24 12:49:36 PM ET
      $CBRG
      Blank Checks
      Finance
    • Amendment: SEC Form SC 13G/A filed by Chain Bridge I

      SC 13G/A - Chain Bridge I (0001845149) (Subject)

      11/13/24 4:37:52 PM ET
      $CBRG
      Blank Checks
      Finance

    $CBRG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Kucharchuk Andrew Albert

      3 - Chain Bridge I (0001845149) (Issuer)

      4/5/24 4:19:27 PM ET
      $CBRG
      Blank Checks
      Finance
    • SEC Form 3 filed by new insider Wiener Oliver

      3 - Chain Bridge I (0001845149) (Issuer)

      2/22/24 4:13:59 PM ET
      $CBRG
      Blank Checks
      Finance
    • New insider Cb Co-Investment Llc claimed ownership of 575,665 units of Class A Ordinary Shares (SEC Form 3)

      3 - Chain Bridge I (0001845149) (Issuer)

      2/20/24 7:34:04 PM ET
      $CBRG
      Blank Checks
      Finance

    $CBRG
    SEC Filings

    See more
    • SEC Form 10-Q filed by Chain Bridge I

      10-Q - Chain Bridge I (0001845149) (Filer)

      11/19/24 5:29:41 PM ET
      $CBRG
      Blank Checks
      Finance
    • Chain Bridge I filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

      8-K - Chain Bridge I (0001845149) (Filer)

      11/19/24 6:05:29 AM ET
      $CBRG
      Blank Checks
      Finance
    • SEC Form NT 10-Q filed by Chain Bridge I

      NT 10-Q - Chain Bridge I (0001845149) (Filer)

      11/14/24 5:29:34 PM ET
      $CBRG
      Blank Checks
      Finance